Brief: Destiny Pharma Announces Deal With Sebela Pharmaceutical For NTCD-M3

Destiny Pharma

24/02/2023 13:35

Feb 24 (Reuters) - Destiny Pharma PLC  DEST.L :
    * DESTINY PHARMA PLC  - AGREEMENT WITH SEBELA PHARMACEUTICAL
FOR
NTCD-M3
    * DESTINY PHARMA PLC - EXCLUSIVE COLLABORATION AND
CO-DEVELOPMENT
AGREEMENT FOR NTCD-M3 WITH SEBELA PHARMACEUTICALS WORTH UP TO
$570M PLUS ROYALTIES
    * DESTINY PHARMA - PARTNERSHIP WITH SEBELA WILL FINANCE
FUTURE
CLINICAL DEVELOPMENT AND COMMERCIALIZATION COSTS OF NTCD-M3 IN
NORTH AMERICA
    * DESTINY PHARMA - CO RETAINS MAJORITY RIGHTS FOR EUROPE AND
ROW

Source text for Eikon:  ID:nRSX0310Ra 
Further company coverage:  DEST.L 
 ((Reuters.Briefs@thomsonreuters.com;))